Syndicate content The Healthcare Sales & Marketing Network
Healthcare Sales & Marketing Network NewsFeed
Updated: 7 min 3 sec ago

pSivida Corp and Hospital for Special Surgery Innovation Center Announce Opening of IND for Sustained-Release Implant for Severe Knee Osteoarthritis

Tue, 08/02/2016 - 21:52
Watertown, MA and New York, NY -- (Healthcare Sales & Marketing Network) -- pSivida Corp. (NASDAQ:PSDV; ASX:PVA), a leader in the development of sustained release drug delivery products for eye diseases, and Hospital for Special Surgery (HSS), America’s le...
Devices, Drug Delivery, Orthopaedic
pSivida, Knee Osteoarthritis, dexamethasone

Meda Shareholders Representing Approximately 94% of Meda Shares Accept Mylan Offer

Tue, 08/02/2016 - 15:58
HERTFORDSHIRE, England and PITTSBURGH, Aug. 2, 2016 -- (Healthcare Sales & Marketing Network) -- The Offer is not being made, and this press release may not be distributed, directly or indirectly, in or into, nor will any tender of shares be accepted from...
Biopharmaceuticals, Mergers & Acquisitions
Mylan, Meda AB

Sensus Healthcare, Inc. Names Anthony Petrelli to its Board of Directors

Tue, 08/02/2016 - 15:55
BOCA RATON, Fla., Aug. 2, 2016 -- (Healthcare Sales & Marketing Network) -- Sensus Healthcare, Inc. (SRTS), a medical device company specializing in the treatment of non-melanoma skin cancers and other skin conditions, such as keloids, with superficial ra...
Devices, Dermatology, Oncology, Personnel
Sensus Healthcare, superficial radiation therapy, skin cancer

Ortho Clinical Diagnostics Announces Ortho Care

Tue, 08/02/2016 - 15:52
RARITAN, N.J., Aug. 2, 2016 -- (Healthcare Sales & Marketing Network) -- Today, Ortho Clinical Diagnostics, a global leader of in vitro diagnostics, announced Ortho Care™, a comprehensive collection of high-quality lab services and resources provided to O...
Diagnostics, Product Launch
Ortho Clinical Diagnostics, Ortho Care

Accera Appoints C. Evan Ballantyne as Chief Financial Officer

Tue, 08/02/2016 - 15:48
BOULDER, Colo., Aug. 2, 2016 -- (Healthcare Sales & Marketing Network) -- Accera, Inc., a clinical-stage biotechnology company focused on product development for Alzheimer's disease, today announced the appointment of C. Evan Ballantyne as chief financial...
Biopharmaceuticals, Neurology, Personnel
Accera, Alzheimer's disease

GORE(R) TIGRIS(R) Vascular Stent Gains FDA Approval for Treatment of Peripheral Artery Disease

Tue, 08/02/2016 - 13:05
FLAGSTAFF, Ariz.--(Healthcare Sales & Marketing Network)--W. L. Gore & Associates, Inc. (Gore) today announced the U.S. Food and Drug Administration (FDA) approval of the GORE® TIGRIS® Vascular Stent, a dual-component stent with a unique fluoropoly...
Devices, Interventional, FDA
W. L. Gore, TIGRIS Vascular Stent, nitinol, Peripheral Artery Disease

Orexigen Completes Acquisition of All U.S. Rights to Contrave(R) and Launches U.S. Sales Organization

Mon, 08/01/2016 - 15:42
SAN DIEGO, Aug. 1, 2016 -- (Healthcare Sales & Marketing Network) -- Orexigen Therapeutics (OREX) announced today that it has successfully completed its previously announced acquisition of the United States rights to Contrave® (naltrexone HCl/bupropio...
Biopharmaceuticals, Acquisitions, Product Launch
Orexigen Therapeutics, Contrave, naltrexone, bupropion

Ipsen Biopharmaceuticals, Inc. Announces FDA Approval of Dysport(R) (Abobotulinumtoxin A) for the Treatment of Lower Limb Spasticity in Pediatric Patients Aged Two and Older

Mon, 08/01/2016 - 15:37
BASKING RIDGE, N.J., Aug. 1, 2016 -- (Healthcare Sales & Marketing Network) -- Ipsen Biopharmaceuticals, Inc., a subsidiary of Ipsen SA (Euronext: IPN; ADR: IPSEY) (Ipsen), today announced that the U.S. Food and Drug Administration (FDA) has approved its ...
Biopharmaceuticals, FDA
Ipsen Biopharmaceuticals, Dysport, abobotulinumtoxin A, botulinum toxin

Varian Medical Systems Selected to Supply First Modern Radiotherapy Systems in Ethiopia

Mon, 08/01/2016 - 15:32
PALO ALTO, Calif., Aug. 1, 2016 -- (Healthcare Sales & Marketing Network) -- Cancer patients in Ethiopia will gain access to modern radiotherapy treatments for the first time with the announcement that Varian Medical Systems (VAR) has been selected to sup...
Devices, Oncology
Varian Medical Systems, radiotherapy, linear accelerator

Cantel Medical Names Jorgen B. Hansen as New President and CEO

Mon, 08/01/2016 - 15:30
LITTLE FALLS, N.J., Aug. 1, 2016 -- (Healthcare Sales & Marketing Network) -- CANTEL MEDICAL CORP. (CMN) announced today the appointment of Jorgen B. Hansen as the Company's President and Chief Executive Officer, effective today, consistent with the Compa...
Devices, Personnel
Cantel Medical

Mylan Launches Generic Dexedrine(R) Capsules

Mon, 08/01/2016 - 15:28
HERTFORDSHIRE, England and PITTSBURGH, Aug. 1, 2016 -- (Healthcare Sales & Marketing Network) -- Mylan N.V. (NASDAQ, TASE: MYL) today announced the U.S. launch of Dextroamphetamine Sulfate Extended-release Capsules, 5 mg, 10 mg, and 15 mg, a generic versi...
Biopharmaceuticals, Generics, Product Launch
Mylan, Dextroamphetamine, Dexedrine, narcolepsy

Bioniz Therapeutics Closes Series A Financing and Appoints David Pyott as Chairman of the Board of Directors

Mon, 08/01/2016 - 15:26
IRVINE, Calif., Aug. 1, 2016 -- (Healthcare Sales & Marketing Network) -- Bioniz Therapeutics, Inc., a biopharmaceutical company leading the discovery and development of first-in-class peptide therapeutics that selectively and simultaneously inhibit multi...
Biopharmaceuticals, Venture Capital, Personnel
Bioniz Therapeutics, peptide therapeutics

Sorrento Therapeutics Announces the Appointment of Dr. Yue Alexander Wu to its Board of Directors

Mon, 08/01/2016 - 15:24
SAN DIEGO, Aug. 1, 2016 -- (Healthcare Sales & Marketing Network) -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE; "Sorrento"), an antibody-centric, clinical-stage biopharmaceutical company developing new treatments for cancer and other unmet medic...
Biopharmaceuticals, Oncology, Personnel
Sorrento Therapeutics, resiniferatoxin

Mylan Launches Generic Propecia(R) Tablets

Mon, 08/01/2016 - 15:22
HERTFORDSHIRE, England and PITTSBURGH, Aug. 1, 2016 -- (Healthcare Sales & Marketing Network) -- Mylan N.V. (NASDAQ, TASE: MYL) today announced the U.S. launch of Finasteride Tablets USP, 1 mg, a generic version of Merck's Propecia®. Mylan received fi...
Biopharmaceuticals, Generics, Product Launch
Mylan, Finasteride, Propecia, androgenetic alopecia

Shire Announces FDA Approval of adynovate with BAXJECT III Reconstitution System

Mon, 08/01/2016 - 14:58
LEXINGTON, Massachusetts, August 1, 2016 -- (Healthcare Sales & Marketing Network) -- Shire plc (LSE: SHP, NASDAQ: SHPG) announced that the U.S. Food and Drug Administration (FDA) has approved the BAXJECT III reconstitution system for ADYNOVATE [Antihemop...
Biopharmaceuticals, FDA
Shire plc, BAXJECT III, reconstitution system

Ipsen Announces FDA Approval of Dysport(R) (abobotulinumtoxinA) for Injection for the Treatment of Lower Limb Spasticity in Children Aged Two and Older

Mon, 08/01/2016 - 14:13
PARIS--(Healthcare Sales & Marketing Network)--Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven pharmaceutical group, today announced that the U.S. Food and Drug Administration (FDA) has approved Dysport® (abobotulinumtoxinA) for injection ...
Biopharmaceuticals, FDA
Ipsen, Dysport, abobotulinumtoxinA, lower limb spasticity

Roche receives CLIA waiver for cobas(R) Influenza A/B and RSV test for the cobas(R) Liat(R)

Mon, 08/01/2016 - 13:03
PLEASANTON, Calif., Aug. 1, 2016 -- (Healthcare Sales & Marketing Network) -- Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has granted 510(k) clearance and CLIA (Clinical Laboratory Improvement Amendmen...
Diagnostics, FDA
Roche Group, cobas Liat, Influenza A/B

Micro Interventional Devices, Inc. Receives FDA Market Clearance for Permaseal(TM)

Fri, 07/29/2016 - 15:00
NEWTOWN, Pa., July 29, 2016 -- (Healthcare Sales & Marketing Network) -- Micro Interventional Devices, Inc.™ (MID), the world leader in minimally invasive and catheter-based compliant fixation technologies addressing structural heart disease announced tod...
Devices, Cardiology, Surgery, FDA
Micro Interventional Devices, Permaseal, transapical access

Edge Therapeutics Announces First Patient Treated in Phase 3 NEWTON 2 Study of EG-1962 in Adult Patients with Aneurysmal Subarachnoid Hemorrhage

Fri, 07/29/2016 - 13:37
Pivotal, double-blind, placebo-controlled global study will compare EG-1962 to standard of care oral nimodipine BERKELEY HEIGHTS, N.J., July 29, 2016 -- (Healthcare Sales & Marketing Network) -- Edge Therapeutics, Inc. (EDGE), a clinical-stage biotechno...
Biopharmaceuticals, Neurosurgery
Edge Therapeutics, NEWTON 2, subarachnoid hemorrhage, aneurysm, nimodipine

VytronUS, Inc. Raises $49 Million in Series C Financing

Fri, 07/29/2016 - 13:26
SUNNYVALE, Calif., July 29, 2016 -- (Healthcare Sales & Marketing Network) -- VytronUS, Inc. ("VytronUS"), a privately held medical device company developing novel technologies for the treatment of cardiac arrhythmias, announced today that it ha...
Devices, Cardiology, Venture Capital
VytronUS, Low-Intensity Collimated Ultrasound, LICU, atrial fibrillation

Contact us     New York    l    Miami    l    Sao Paulo     l    Mexico DF    l    London    l    Hong Kong